Wikipedia -WSS

Wikipedia

author：comprehensive 2025-10-01 22:48:42 - browse：93

Adam's take main illustration — Molly Ferguson/STAT

Anavex Life Sciences is in a tough spot. The serial dissembler of clinical trial results might be forced, finally, to tell the truth when it reads out its next study in Rett syndrome.

What sets Anavex apart from all the other biotechs on my radar screen is its habit of shifting the goalposts on clinical trials. Twice last year, first in February and then in December, Anavex announced “positive” outcomes from studies of its drug called blarcamesine — except the results were derived from efficacy endpoints that were not part of the original study designs.

If blarcamesine fails to achieve the pre-determined goals of clinical trials, the thinking apparently goes, then just make a post-hoc change to the study goals.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Orangutan used medicinal plant to treat wound, first time ever seen

WSS

MultiPlan and major insurers sued for alleged medical price

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

H5N1 bird flu found in pasteurized milk: what we know

Surge of respiratory disease in China has likely explanation

Diversity in clinical trials starts with building trust, experts say

Cue Health's Covid

hotspot

Wikipedia

knowledge

Apple is now the first public company to be valued at $3 trillion

FTC falls short on scrutinizing hospital mergers, study says

Continuity nursing helped my family in our darkest PICU moments

Childhood cancer progress stalls for Black, Hispanic kids: Report

The cancer drug shortage isn’t new — and neither are the solutions

Getting Alzheimer's drug Leqembi to patients can be a challenge

The high cost of giving birth even with insurance

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Medicare details structure of new drug price negotiation program

Why rehabilitation engineers need to center patients in their research

knowledge

Cue Health's Covid

Cell therapy fails to slow type 1 diabetes, but safety is established

Weight loss drug costs may need more research, senator suggests

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Dogs on Prozac: What pet anti

Weight loss drug costs may need more research, senator suggests

explore

focus

knowledge

knowledge